DYMO® Partners with ELLKAY to Elevate the Healthcare Community with New Lab Enterprise Platform LKOrbit / The innovative cloud-based connectivity platform will expand outreach, streamline operations and increase revenue.
Today, DYMO®, a leading provider of innovative labeling solutions and part of the Newell Brands global portfolio, announces its partnership with ELLKAY, a nationwide leader in healthcare interoperability for more than 20 years. Through this collaboration, ELLKAY's LKOrbit platform — a lab enterprise solution designed to streamline medical and laboratory workflows — will integrate seamlessly with DYMO's trusted labeling solutions. This partnership provides a comprehensive solution for laboratories and clinics of all sizes, helping them improve efficiency and accuracy in their organizational processes.
'For years, DYMO has been a go-to labeling tool for those in the healthcare field. From quickly and easily creating file folder labels, barcode labels for inventory and specimen tracking and more, we work hand-in-hand with healthcare workers to ensure a seamless and trusted medical environment.' Liesbet De Soomer, Global Marketing Director DYMO at Newell Brands explains. 'We are constantly developing new innovations to help our partners streamline operations and LKOrbit was designed to meet the unique needs of any medical center, whether a large hospital group or a local private practice.'
The LKOrbit Platform was designed to work in conjunction with DYMO's trusted solutions to support both clinical and business needs by eliminating workflow challenges and enabling electronic ordering, including the results of laboratory testing. Key features and platform highlights include:
Demographic, insurance, and clinical data on demand
Patient self-service for both registration and testing
End-to-end orders and results
LOINC, test code and insurance code mapping
Eligibility benefits verification
Automatic state reporting
Secure delivery of results to patients & providers
Surveillance & pooled testing
'ELLKAY is dedicated to supporting healthcare providers with consumer-first innovations', said Ajay Kapare, President & CEO at ELLKAY. 'Our partnership with DYMO allows us to keep delivering cutting-edge communication solutions for healthcare organizations by providing an integrated environment which is able to handle complex orders and live clinical data.'
Learn more at www.ellkay.com/lkorbit.
About ELLKAY:
ELLKAY is a trusted enterprise data management partner, driving innovation and connectivity across the healthcare ecosystem. Since 2002, ELLKAY has empowered hospitals, laboratories, payers, healthcare IT vendors, and more with unmatched data management expertise. With connections to over 58,000 practices and interoperability with 750+ EHR/PM systems across 1,100+ versions, ELLKAY delivers solutions that streamline data exchange, fuel value-based care, and drive smarter decision making. Discover more at ELLKAY.com and connect with us on YouTube, LinkedIn, X/Twitter, or via [email protected].
About DYMO®: DYMO® is a leading global provider of innovative labeling solutions, offering a wide range of products designed to meet the diverse labeling needs of businesses and consumers worldwide.
About Newell Brands:
www.newellbrands.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split
OCALA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (OTC Pink: AIMID) (NYSE American: AIM) ('AIM' or the 'Company') today announced a reverse stock split ('Reverse Stock Split') of its shares at a ratio of 1-for-100. The Reverse Stock Split will take effect at market open tomorrow, June 12, 2025. The Company's ticker symbol on the OTC Pink will be AIMID for 20 trading days, including the effective date. One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Company's common stock to enable the Company to regain compliance with the NYSE American's Listing Qualifications. At a Special Meeting of Stockholders held on April 30, 2025, the Company's stockholders approved a series of alternate amendments to the Company's Certificate of Incorporation to effect a reverse stock split of the Company's outstanding common stock at a ratio in the range of up to 1-for-100, with such ratio to be determined by the Company's Board of Directors. Stockholders will be given cash in lieu of any fractional shares on a post-split basis. Following the Reverse Stock Split, the new CUSIP number of the common stock will be 00901B303, with the par value per share of common stock remaining at $0.001. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the 'PSLRA'). Words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'continue,' 'believe,' 'potential,' 'upcoming' and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@
Business Wire
27 minutes ago
- Business Wire
Great Point Partners Acquires Majority Stake in Eutecma – Sustainable Temperature Controlled Pharmaceutical Packaging
GREENWICH, Conn.--(BUSINESS WIRE)-- Great Point Partners ('GPP' or 'the Firm'), a Greenwich-based private investment firm focused exclusively on the health care industry, announced today the acquisition of a majority stake in Eutecma (or 'the Company'), a German-based developer of sustainable, modular, and reusable temperature controlled packaging solutions for pharmaceutical cold chain shipments. 'Nearly 17 years later we have the chance to make even greater strides, and we're thrilled to have GPP's support in this next phase of growth.' - Eutecma Co-Founder, Markus Baumgärtner Share Since its founding in 2008, Eutecma has been committed to producing passive cooling systems that make transport and logistics more sustainable and efficient. Eutecma is a leader in the pharmaceutical industry with its patented ICECATCH ® cooling systems being a top choice among pharmaceutical, medical, and laboratory diagnostics businesses. Eutecma's ' retecma ' has created a circular system for its packaging materials with an extensive network of Refreshment Centers. The process ensures materials remain in circulation for as long as possible while shrinking carbon dioxide (CO 2) emissions, and provides real-time CO 2 reduction data to clients. 'We have successfully created innovative and sustainable cold chain solutions that have proven themselves with well-known pharmaceutical customers,' said Eutecma Co-Founder, Florian Zeilfelder. 'Our work with GPP will advance that mission so we can strategically expand our reach, especially in the US and other geographies around the world.' 'Florian and I took a leap of faith when founding Eutecma because we knew we had an innovative idea for our industry,' said Eutecma Co-Founder, Markus Baumgärtner. 'Nearly 17 years later we have the chance to make even greater strides, and we're thrilled to have GPP's support in this next phase of growth.' With this partnership, Eutecma has also acquired Resolvision, Eutecma's proprietary re-use machine technology utilized at its Refreshment Centers. 'Eutecma impressed us with their innovative technology and approach to sustainability that is making a significant impact for pharmaceutical clients,' said Eddie Hjerpe, Senior Vice President at GPP. 'Their temperature performance, CO 2 reduction data, and differentiated engineering is exactly what the evolving cold-chain industry is looking for today.' 'Eutecma has the opportunity to further expand its global capabilities at a time when there's growing demand for reusability, cost-savings, and new cooling technologies within cold chain,' said Harrison Johnson, Vice President at GPP. 'This investment underscores our dedication to supporting exceptional high growth health care companies that assist in bringing lifesaving medicines to patients across the globe.' About Great Point Partners Great Point Partners ( founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 32 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP IV. Great Point manages approximately $1.5 Billion of capital in its private funds and public biotechnology equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, contract manufacturing and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. About Eutecma Founded in 2008 by co-founders Florian Zeilfelder and Markus Baumgärtner, Eutecma ( is a leading designer and manufacturer of sustainable, modular, and reusable temperature controlled packaging solutions for pharmaceutical clients. The Company is headquartered in Mannheim, Germany with Refreshment Centers in the EU and U.S. Eutecma's product portfolio is designed to be reused for multiple shipments, which enables clients to meet their sustainability initiatives while simultaneously yielding lower upfront and total cost of shipment compared to other TCP solutions. To pair with its reusable TCP solutions, Eutecma's 'retecma' program enables the evaluation of used packaging at their Refreshment Centers for evaluation and refurbishment before reusing or recycling the solutions for future shipments. This refurbishment process creates a circular economy whereby Eutecma products are reused until their end of life, at which point they are recycled creating a fully circular, sustainable economy.
Yahoo
28 minutes ago
- Yahoo
Allarity Therapeutics Announces Changes to Board of Directors
TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. ('Allarity' or the 'Company') (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company's Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity's development over the past two years. Mr. Høiland is already well-acquainted with Allarity's mission and operations, having served as a strategic consultant to the Company since October 2024. Jesper Høiland is a highly respected industry leader with more than 30 years of experience in global pharmaceutical commercialization and executive leadership. He previously served as President and EVP of Novo Nordisk's U.S. operations, where he led major product launches, pricing strategies, and infrastructure expansion. In addition, he held senior executive roles as President and CEO of Radius Health and as Global Commercial Officer at Ascendis Pharma. Mr. Høiland currently serves as Chairman of SciBase Holding AB and is a board member of ALK-Abello A/S and Flen Health SA. 'We are pleased to welcome Jesper Høiland to the Allarity Board during a period of growing clinical momentum,' said Jerry McLaughlin, Chairman of the Board of Directors at Allarity Therapeutics. 'On behalf of the entire Board, I would also like to thank Joseph Vazzano for his contributions to Allarity. His financial expertise and thoughtful guidance helped strengthen our governance and operational focus during a critical time. We are grateful for his service and wish him the very best in his ongoing endeavors.' Thomas Jensen, CEO of Allarity Therapeutics, added: 'Since Jesper started working with us in his consultancy capacity, I have several times benefited from his experience and strategic advice. His deep understanding of how to prepare for the commercialization phase of an investigational drug, his extensive global network—built over decades at Novo Nordisk—and his proven leadership during periods of strategic transition at Radius Health will certainly be valuable to Allarity. It is very positive that he will now be even more closely engaged with the Company, as we prepare for the next phases of clinical development and potential later commercialization of stenoparib.' About StenoparibStenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and the Drug Response Predictor – DRP® Companion DiagnosticAllarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed Allarity TherapeuticsAllarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit Follow Allarity on Social MediaLinkedIn: Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The words 'anticipates,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predicts,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the anticipated contributions of Jesper Høiland to Allarity's strategic direction; expectations about the Company's clinical and commercial development of stenoparib; the Company's ability to benefit from enhanced leadership and governance; and the potential future impact of board changes on corporate strategy and stakeholder value. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to risks related to changes in leadership not yielding expected outcomes; uncertainties around clinical development timelines; risks that clinical data may not support regulatory approval or commercial viability; and the general risks associated with operating a clinical-stage biopharmaceutical company. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in our Form 10-K annual report filed with the Securities and Exchange Commission (the 'SEC') on March 31, 2025, available at the SEC's website at and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. ### Company Contact: investorrelations@ Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 tsp@ Attachment Allarity Therapeutics Press Release - Announces Changes to Board of DirectorsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
